WHAT’S OUR STORY?

We are on a mission to impact patients’ lives.

We have potentially groundbreaking clinical-stage therapies in development that, if approved, offer an innovative approach to essential areas of dermatology.

OUR STORY STARTS HERE

We are proud to announce the FDA approval of our first treatment
WINLEVI® (clascoterone) cream 1%

Read more

LATEST NEWS

November 18, 2021
chevron right icon

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE INTERIM RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A. AND DECLARE THE OFFER SUCCESSFUL

November 16, 2021
chevron right icon

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH PROVISIONAL INTERIM RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

November 3, 2021
chevron right icon

Cassiopea SpA announces the US launch of Winlevi® (clascoterone cream 1%)

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.